Compare ADVM & RFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADVM | RFM |
|---|---|---|
| Founded | 2006 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 86.2M |
| IPO Year | 2014 | N/A |
| Metric | ADVM | RFM |
|---|---|---|
| Price | $4.16 | $14.14 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.60 | N/A |
| AVG Volume (30 Days) | ★ 372.0K | 20.7K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.74% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,191.10 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.78 | $12.89 |
| 52 Week High | $6.98 | $16.41 |
| Indicator | ADVM | RFM |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 39.26 |
| Support Level | $4.07 | $13.98 |
| Resistance Level | $4.23 | $14.19 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 50.31 | 14.75 |
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.